Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**gaba + red yeast rice** is a *combination dietary supplement* composed of γ-aminobutyric acid (GABA) and red yeast rice. GABA is an amino acid neurotransmitter with physiological roles in blood pressure modulation and nervous system function. Red yeast rice is produced by fermenting rice with the yeast *Monascus purpureus*, yielding a product high in monacolins (notably monacolin K, which is chemically identical to lovastatin), as well as other bioactives such as GABA and various polyketides. Red yeast rice is primarily used for managing dyslipidemia by inhibiting cholesterol biosynthesis via HMG-CoA reductase inhibition, with additional effects including reduced blood pressure and potential anti-obesity properties attributed to GABA and other minor peptide constituents[2][3][5]. The product is marketed as a dietary supplement, not an approved pharmaceutical, and product quality (e.g., monacolin K/gaba content) may vary[5][7]. The combination leverages the lipid-lowering action of red yeast rice and the antihypertensive effects of GABA for cardiovascular health support[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gaba + red yeast rice.